RBC Europe’s Applied Therapeutics APLT Stock Holding History

RBC Europe’s Portfolio APLT Stock Details APLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-365	Closed	-$8.03K	–	1185
2020 Q4	$8.03K	Buy	+365	New	+$7.6K	﹤0.01%	911

Other funds holding APLT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

RBC Europe's APLT Position: Q1 2021 in Review

RBC Europe sold out of Applied Therapeutics (APLT) in Q1 2021, closing a stake of 365 shares — an estimated $8.03K sold.

RBC Europe first reported a position in APLT in Q4 2020 and held it in 1 quarter. The position peaked at $8.03K in Q4 2020. 67 funds tracked by Wall St. Rank hold APLT as of Q1 2021.

RBC Europe reported no remaining Applied Therapeutics position as of Q1 2021 after selling out during the quarter.
RBC Europe sold 365 Applied Therapeutics shares in Q1 2021, an estimated $8.03K.
RBC Europe first reported a position in Applied Therapeutics in Q4 2020 and held it in 1 quarter.
RBC Europe's Applied Therapeutics position peaked at $8.03K in Q4 2020.
67 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2021.

Based on RBC Europe's 13F filing for Q1 2021, filed 9 Nov 2023.